Compare AREC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AREC | HELP |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.5M | 281.4M |
| IPO Year | N/A | N/A |
| Metric | AREC | HELP |
|---|---|---|
| Price | $3.12 | $4.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.50 | ★ $95.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.1M |
| Earning Date | 03-27-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42,083.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $4.52 |
| 52 Week High | $7.11 | $8.55 |
| Indicator | AREC | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 35.51 |
| Support Level | $2.96 | N/A |
| Resistance Level | $3.30 | $7.28 |
| Average True Range (ATR) | 0.24 | 0.57 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 37.31 | 5.71 |
American Resources Corp constructs and/or purchases and manages a chain of combined gasoline, diesel and natural gas (NG) fueling and service stations; construct conversion factories to convert NG to liquefied natural gas (LNG) and compressed natural gas (CNG); and construct conversion factories to retrofit vehicles currently using gasoline or diesel fuel to also run on NG in the United States and also to build a convenience store to serve its customers in each of its locations. Its segments are AIC focused on the extraction, processing, transportation, and distribution of coal for a variety of industries, with a focus on metallurgical quality coal to the steel industry; RLMT; and EMC.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.